INTRODUCTION
Osteopetrosis (OP) is a generic diagnosis for a group of inherited sclerosing bone diseases caused by absence or defective function of osteoclasts 1 . Defective osteoclastic bone resorption leads to partial or complete encroachment of bone marrow spaces, with increased skeletal mass and bone density. This triggers severe clinical complications such as extra-medullary hematopoiesis, cytopenia, hepato-splenomegaly, macrocephaly and recurrent bone fractures. Compression of cranial nerves is responsible for several neurological deficits, such as facial and trigeminal neuropathies, hearing loss, hydrocephalus and developmental delay. Importantly, blindness can occur very early in life, due to compression of the optic nerve 2, 3 .
Without medical treatment, infantile OP has a poor prognosis, and the majority of patients die before the age of 10 years due to hemorrhage or infections 4 .
Hematopoietic stem cell transplantation (HSCT) is the only curative approach for most children with infantile OP, since the engraftment of donor-derived functional osteoclasts can result in bone remodeling and re-establishment of normal hematopoiesis 5 . If HSCT is performed early, this can effectively prevent serious complications, such as blindness, bone fractures, hydrocephalus and nerve compression.
Nevertheless, HSCT in children with OP is complicated by a high incidence of graft failure and increased transplant-related toxicity, mainly involving lungs and liver, particularly when using alternative stem cell donors.
Since timing of transplantation is critical in OP, umbilical cord blood represents an attractive stem cell source for HSCT, due to its prompt availability and also the decreased incidence of acute and chronic GVHD. However, the higher incidence of graft failure and delay of engraftment after umbilical cord blood transplantation (UCBT) may affect the success rate of this procedure.
With the aim to analyze outcomes after UCBT in children with OP we conducted a retrospective analysis of 51 children affected by infantile OP reported to Eurocord.
METHODS

Inclusion Criteria
This retrospective study is based on data of children with infantile OP who were given UCBT and were reported to Eurocord from 21 EBMT centers and Duke University Medical Center, through a questionnaire concerning the patients and disease characteristics. Eurocord has collected data on UCBT performed within and outside Europe since 1989 and more than 15,000 transplants have been registered. Using the Eurocord data-base we identified centers that had performed UCBT for infantile OP and sent them a questionnaire asking for permission to enter retrospective data in the study; 22 centers gave their consent (the list of participating centers is reported in the acknowledgement section). All data was checked by a Eurocord medical coordinator and entered the data-base after the transplant centers had been contacted to retrieve missing information.
Definitions and end-points
The main end-point was overall survival (OS), defined as the time between the date of transplantation and the date of death from any cause or the date of the last follow-up for survivors. The other end-points were neutrophil and platelet recovery, occurrence of graft failure and incidence of acute and chronic graft-versus-host disease (GvHD). The date of neutrophil recovery was defined as the first of 3 consecutive days with a neutrophil count of at least 0. Acute GvHD was defined and graded according to international criteria 6 . Chronic GvHD was evaluated considering only patients surviving more than 100 days after transplantation with sustained donor engraftment, using previously published criteria 7 .
Statistical analysis
To analyze risk factors for outcomes, we considered age at transplantation (<0.5 years versus ≥0.5 years), HLA compatibility (6/6 and 5/6 versus 4/6 and 3/6), ABO match (matched versus major or minor incompatibility), median number of infused total nucleated cells and median number of infused CD34+ cells. Cumulative incidence function was calculated for neutrophil recovery, platelet engraftment, acute and chronic GvHD in a competing-risk setting, where death was considered the competing event 8 . Gray test was used for univariate comparisons. Probability of OS was calculated using the Kaplan-Meier estimate; the two-sided log-rank test was used for univariate comparisons. Multivariate models were not performed due to small number of patients. Statistical analyses were performed using SPSS (Inc., Chicago) and S-Plus (MathSoft, Inc, Seattle) software packages.
RESULTS
Patient, disease and transplant characteristics
The characteristics of the patients and their transplants are summarized in Table 1 and 2.
The median age at UCBT was 0.56 (range 0.08-7.43) years. The majority of patients with a known genetic diagnosis were found to have the common TCIRG1 mutation (87%). Visual impairment was experienced by 25/35 evaluable patients (71%), while hearing impairment by 5/30 evaluable children (16%). Mild neurodevelopmental delay was reported in 9/26 evaluable patients (35%). Neurological status was reported to be mildly abnormal in 10/33 evaluable patients (30%) and severely abnormal in one (3%). Pre-transplant MRI/CT of the brain showed abnormalities in 84% of evaluable patients (27/32). Most children (90%) had abnormal hematology results (anemia, thrombocytopenia and leukocytosis or neutropenia) at time of UCBT. Hepato-splenomegaly was present in 50% evaluable children.
Hypocalcemia was experienced by 22/32 evaluable patients (68%). The majority of the treated children presented short stature (28/34, 82%) or failure to thrive (16/51, 31%). Bone fractures were experienced in 6/34 evaluable patients (17%).
The median infused total nucleated cell count (TNCC) was 13. 
Engraftment
The cumulative incidence (CI) of neutrophil recovery at day 60 was 67%. The median time to neutrophil recovery was 23 (range, 10-68) days. In univariate analysis the probability of neutrophil recovery was not statistically associated with age at transplantation, conditioning regimen, infused TNCC or CD34+ cell dose or HLA disparity.
The CI of platelet recovery at 180 days was 45%. The median time to platelet recovery was 54 days (range, 15-142).
Seventeen patients (33%) experienced graft failure. Information on treatment following graft failure was available for 5/17 children: all 5 patients underwent a second HSCT and 2 children are alive at last follow-up.
Chimerism results were available in 32 engrafted patients. Twenty-six patients (81%) achieved full donor engraftment, while six children (19%) experienced mixed donor engraftment. All children treated with Treosulfan-based conditioning (5/5) experienced donor engraftment and at last follow-up 2/3 alive patients had full donor engraftment, while one patient presented mixed donor engraftment.
GvHD and transplant-related morbidity
The CI of grade II-IV acute GvHD was 31% (n=17); in detail, 8, 4 and 5 patients experienced grade II, grade III and grade IV acute GvHD, respectively. The CI of chronic GvHD at 6 years was 21%. In univariate analysis there was no statistically significant association between the incidence of acute and chronic GvHD with infused TNCC, HLA disparity or age at transplantation.
In terms of transplant-related morbidity, 13/34 (38%) evaluable patients had respiratory complications with oxygen requirement and 10/34 (28%) patients required mechanical ventilation. Pulmonary hypertension was reported in 2/34 evaluable patients (6%).
Hypercalcaemia post-UCBT was reported in 10/36 (28%) evaluable patients.
Veno-occlusive disease (VOD) occurred in 6/38 evaluable patients (16%) and 2 children (5%) experienced liver failure. Seventeen patients had received VOD prophylaxis prior to UCBT (Heparin=11/17, Ursodeoxycholic acid= 3/17, Defibrotide=3/17) and 2/17 patients eventually developed VOD. Central nervous system (CNS) toxicity was experienced by 8/35 (23%) evaluable patients (n=1 encephalopathy, n=7 seizures). Renal insufficiency was experienced by 6/35 (17%) evaluable patients.
Overall Survival
The estimated 6-year OS was 43% (Figure 3) , with a median follow-up time of 74 months (range, 6 to 196 months).
Twenty-eight children (55%) died after UCBT, 15 of which after graft failure. The majority of deaths (23/28) occurred within the first year post-transplant.
Causes of death were: infection (46%), GvHD (18%), idiopathic pneumonia syndrome (IPS)/acute respiratory distress syndrome (ARDS) (10%), VOD (7%), hemorrhage (7%) and other (12%) ( Table 3 ).
In univariate analysis there was no statistically significant association between variables such as age at transplantation, year of transplantation, infused CD34+ cell dose, HLA disparity or conditioning regimen and OS
DISCUSSION
This retrospective study describes the outcome of a large cohort of children affected by infantile OP, a rare genetic disorder, undergoing unrelated UCBT. Our analysis confirms that UCBT in children with OP, together with HSCT from other alternative donors, constitutes a significant clinical challenge, due to the high incidence of graft failure and transplant-related mortality 7 in this specific disease.
In our group of patients, the overall survival at 6 years was 43%, a result consistent with those of previously published studies on HSCT from donors other than an HLA-identical Our data shows a high incidence of graft failure after UCBT (33%), which, however, is comparable to that reported by Orchard et al, who found a 1-year probability of graft failure of 34%; in that cohort graft rejection accounted for 43% of deaths in patients transplanted from a donor other than an HLA-identical sibling 10 .
In our cohort only 2/17 (12%) patients who presented graft failure were alive at last followup, confirming that only a minority of children with OP can be rescued after graft rejection.
Compared to other non-malignant diseases with an indication to HSCT, OP is characterized Transplant-related mortality was high in our study: 28/51 children died after UCBT (55%) and, of those patients, 82% died within the first year after transplantation, mostly due to infections (46%), GvHD (18%), ARDS/IPS (10%) or VOD (7%).
The incidence of liver toxicity was high in our cohort, with 6/38 (16%) available patients experiencing VOD and 2/38 (5%) available patients experiencing liver failure after UCBT.
VOD is a severe complication that can occur after HSCT, especially when myeloablative doses of Busulfan and Cyclosphosphamide are used in the conditioning regimen The incidence of pulmonary toxicity was also high in our group of patients: 13/35 (37%) evaluable patients required O2 therapy or mechanical ventilation. This is in keeping with what has been published previously 10 , especially with the use of mismatched donors.
Pulmonary hypertension was reported only in 2 patients; Steward et al reported a high incidence of pulmonary hypertension (29%) in 28 children with OP receiving HSCT 18 . It is possible that some children in this study reported with IPS/ARDS might have suffered from pulmonary hypertension, since this condition might be easily misdiagnosed. It is therefore important that any child with OP who experiences acute respiratory deterioration after HSCT without clear evidence of infection be carefully investigated in order to rule out pulmonary hypertension.
Hypercalcemia after UCBT was reported in 28% evaluable patients: this is a recognized complication that can occur during the first few months after transplantation in children with OP, due to the engraftment of functional, donor-derived osteoclasts. Hypercalcaemic crises are generally treated with hyper-hydration and diuretics and occasionally calcitonin and bisphosphonates are necessary.
In summary, our study shows that UCBT in infantile OP is associated with a high incidence of graft failure and transplant-related mortality. This data confirms that transplantation in children with infantile OP remains problematic when a matched sibling donor is not available and new strategies are needed to improve survival in this group of patients.
HSCT should be performed rapidly in children with preserved vision and it is recommended that, in the absence of a fully matched donor, HSCT from an alternative donor should be offered.
Since many countries do not have the possibility of performing in vitro T-cell depletion and data on the feasibility of using a haploidentical donor with post-HSCT cyclophosphamide is limited 19 , comparative studies should be performed to further evaluate whether UCBT remains a valid alternative for children with OP. 
